Area of research
Cancer Research · Oncology
Research interest
Research interests include Cutaneous Melanoma Detection and Management, Breast Cancer Treatment Studies, Melanoma and MAPK Pathways, and Breast Implant and Reconstruction.
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study
Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma
Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging
Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
Sentinel lymph node biopsy rates in Victoria, 2018 and 2019
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma
Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers
Histological regression in melanoma: impact on sentinel lymph node status and survival
BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting
Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity
Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram
First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
Current management of patients with melanoma who are found to be sentinel node‐positive
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility